Focus of hph Management

Pharmaceutical and Biotechnology Industry Consulting
Business Strategy and Marketing
Executive Management

Personal Profile

Hans Peter Hasler is a senior executive and top-level advisor to the life-sciences industry. He has an international track record and in-depth operational, commercial, and general management expertise. During his career, Mr. Hasler has managed the growth of leading players in the pharmaceutical industry and has successfully launched several blockbuster drugs.

Mr. Hasler is Owner and Managing Director at HPH Management GmbH. HPH Management is consulting for Pharmaceutical and Biotechnological companies with focus on strategy, merger and acquisitions, licensing and marketing.

He was the Chief Executive Officer of Vicarius Pharma AG, a privately held European Bio-Pharma company until 2020. His prior experiences include Elan Corporation, Dublin, where he was Chief Operating Officer, and Biogen Inc., Boston, where his positions included Chief Operating Officer, and EVP, Head of Global Neurology and International.

Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as Senior Vice President, Chief Marketing Officer and beforehand Managing Director of Wyeth Group Germany, Münster.

Hans Peter Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland (SIX), Chairman of the Board of Shield Therapeutics, London (AIM), and a Director of Minerva Neurosciences in Boston (Nasdaq) and Gain Therapeutics, Bethesda (Nasdaq). He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.

Professional Experience

Global Life Sciences Advisor, Switzerland

Chief Executive Officer, Vicarius Pharma, Switzerland

Chief Operating Officer, Elan Pharmaceuticals, Ireland/Switzerland

Chief Operating Officer, Biogen, USA

Head of Global Commercial Operations, Biogen, USA

Chief Marketing Officer, Wyeth, USA

Managing Director, Wyeth, Germany

General Manager, Wyeth, Switzerland/Austria/CEE

Key Achievements

Elan Pharmaceuticals

Trade sale of Tysabri (IV multiple sclerosis compound).

Biogen

Lead in-licensing of Tecfidera (dimethyl fumarate) with annual revenues of over 4 billion USD;
Transferred international headquarters from Paris to Zug, Switzerland and accelerated MS leadership position by optimizing structural and marketing efficiency;
Initiated and planned Biogen`s entry into the biosimilar market segment;
Successfully launched Tysabri globally (annual revenues of 3 billion USD) and monitored regulatory re-entry in Europe.

Wyeth (Global Headquarters)

Supported Wyeth as chief marketing officer and member of the global executive leadership team to achieve revenues of 10 billion USD;
Led the improvement of R&D/business collaborations while co-chairing eight therapeutic business units;
Assumed global launch/post launch responsibility for Enbrel (rheumatoid arthritis), Effexor (antidepressant), and Tazobactam (antibiotic).

Wyeth Group Germany (in charge of DACH-Region)

Reorganized organizational structure in Germany and led successful transformation of a generic product supplier into a state-of-the-art marketing organization;
Managed the successful launch of Effexor (antidepressant), Enbrel (RA) and ReFacto (Factor VIII hemophilia).